Drugs.com - Clinical Trials

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

COPENHAGEN, Denmark; March 17, 2025 -- Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FRα)-targeted...

Mar 19, 2025 - 22:55
 0
Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer
COPENHAGEN, Denmark; March 17, 2025 -- Genmab A/S (Nasdaq: GMAB) announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FRα)-targeted...
Read More

Tags:

Previous Article

Airbnb Calls Vrbo Billboards 'Confused' and 'Desperate'

Next Article

More “Beautiful, Clean Coal” Power Coming To US Thanks To America’s Ayatollah

Related Posts

Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

Crinetics Announces Positive Topline Results From Phase...

Feb 9, 2025  0

Nipocalimab, the First and Only Investigational Treatment to be Granted U.S. FDA Breakthrough Therapy Designation for the Treatment of Adults with Moderate-to-Severe Sjögren’s Disease, has now Received Fast Track Designation

Nipocalimab, the First and Only Investigational Treatme...

Mar 19, 2025  0

Pila Pharma Announces XEN-D0501 Preclinical Proof-of-Concept Achieved In Cardiovascular Disease Study

Pila Pharma Announces XEN-D0501 Preclinical Proof-of-Co...

Feb 9, 2025  0